Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 30:13:1759720X211040696.
doi: 10.1177/1759720X211040696. eCollection 2021.

Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review

Affiliations
Review

Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren's syndrome: a literature review

Roberto Depascale et al. Ther Adv Musculoskelet Dis. .

Abstract

Lung involvement in systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS) has extensively been outlined with a multiplicity of different manifestations. In SLE, the most frequent finding is pleural effusion, while in pSS, airway disease and parenchymal disorders prevail. In both cases, there is an increased risk of pre-capillary and post-capillary pulmonary arterial hypertension (PAH) and pulmonary venous thromboembolism (VTE). The risk of VTE is in part due to an increased thrombophilic status secondary to systemic inflammation or to the well-established association with antiphospholipid antibody syndrome (APS). The lung can also be the site of an organ-specific complication due to the aberrant pathologic immune-hyperactivation as occurs in the development of lymphoma or amyloidosis in pSS. Respiratory infections are a major issue to be addressed when approaching the differential diagnosis, and their exclusion is required to safely start an immunosuppressive therapy. Treatment strategy is mainly based on glucocorticoids (GCs) and immunosuppressants, with a variable response according to the primary pathologic process. Anticoagulation is recommended in case of VTE and multi-targeted treatment regimens including different drugs are the mainstay for PAH management. Antibiotics and respiratory physiotherapy can be considered relevant complement therapeutic measures. In this article, we reviewed lung manifestations in SLE and pSS with the aim to provide a comprehensive overview of their diagnosis and management to physicians taking care of patients with connective tissue diseases.

Keywords: primary Sjogren’s syndrome; pulmonary involvement; systemic inflammation; systemic lupus erythematosus; therapeutic strategies.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Areas of bilateral parenchymal consolidations with a peribronchovascular distribution localized in the inferior lobes on high-resolution computed tomography (a) and the corresponding chest radiography image (b) in a patient with organizing pneumonia in systemic lupus erythematosus.
Figure 2.
Figure 2.
Diffuse ground glass opacities, air-bronchogram images, and bilateral pleural effusion on high-resolution computed tomography in a patient with hemorragic alveolitis in systemic lupus erythematosus before (a) and after (b) methylprednisolone pulses and high-dose intravenous glucocorticoid therapy.
Figure 3.
Figure 3.
Reticular pattern during inspiration (a) and expiration (b) on high-resolution computed tomography in a patient affected with follicular bronchiolitis in primary Sjögren’s syndrome.

References

    1. Zanatta E, Codullo V, Avouac J, et al.. Systemic sclerosis: recent insight in clinical management. Joint Bone Spine 2020; 87: 293–299. - PubMed
    1. Gasparotto M, Gatto M, Saccon F, et al.. Pulmonary involvement in antisynthetase syndrome. Curr Opin Rheumatol 2019; 31: 603–610. - PubMed
    1. Keane MP, Lynch JP, III. Pleuropulmonary manifestations of systemic lupus erythematosus. Thorax 2000; 55: 159–166. - PMC - PubMed
    1. Gatto M, Zen M, Ghirardello A, et al.. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013; 12: 523–536. - PubMed
    1. Quadrelli S, Alvarez C, Arce S, et al.. Pulmonary involvement of systemic lupus erythematosus: analysis of 90 necropsies. Lupus 2009; 18: 1053–1060. - PubMed